Menopur

Menopur

menotrophin

Manufacturer:

Ferring

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Per 75 IU vial Highly purified menotrophin 75 IU FSH & 75 IU LH. Per 600 IU vial Highly purified menotrophin corresponding to 600 IU FSH & 600 IU LH.  Per 1,200 IU vial Highly purified menotrophin corresponding to 1,200 IU FSH & 1,200 IU LH
Indications/Uses
Infertility in anovulation, including polycystic ovarian disease (PCOD), in women who have been unresponsive to treatment w/ clomiphene citrate; controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART) (eg, in vitro fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) & intracytoplasmic sperm injection (ICSI). Stimulation of follicular development in women w/ hypogonadotrophic hypogonadism.
Dosage/Direction for Use
SC/IM Individualised dosage. Women w/ anovulation including PCOD Initially 75-150 IU daily for 7 days w/in the initial 7 days of the menstrual cycle. Recommended dose increment: 37.5 IU/adjustment, not exceeding 75 IU. Max daily dose: 225 IU. When an optimal response is obtained, administer single inj of 5,000-10,000 IU hCG 1 day after the last Menopur inj. Women undergoing controlled ovarian hyperstimulation for multiple follicular development ART Initially 150-225 IU daily for the first 5 days. Therapy should start approx 2 wk after the start of agonist treatment. Max: 450 IU daily. Do not exceed dosing beyond 20 days.
Contraindications
Hypersensitivity. Tumours of the pituitary gland or hypothalamus; ovarian, uterine or mammary carcinoma; gynaecological haemorrhage of unknown aetiology; ovarian cysts or enlarged ovaries not due to polycystic ovarian disease. Patients w/ primary ovarian failure & malformation of sexual organs & fibroid tumours of the uterus incompatible w/ pregnancy. Pregnancy & lactation.
Special Precautions
Assess infertility & evaluate putative contraindications for pregnancy; hypothyroidism, adrenocortical deficiency, hyperprolactinaemia & pituitary or hypothalamic tumors & appropriate specific treatment given. Withhold human chorionic gonadotrophin (hCG) & refrain from coitus or use barrier methods for 4 days if ovarian hyperstimulation occurs. Discontinue use if severe ovarian hyperstimulation syndrome (OHSS) occurs. High risk of multiple pregnancy. History of tubal disease are at risk of ectopic pregnancy. Risk of ovarian & other reproductive system neoplasms. Congenital malformation. Family history, severe obesity (BMI >30 kg/m2) or thrombophilia.
Adverse Reactions
Abdominal pain, nausea, enlarged abdomen. Inj site reaction &/or pain. Headache. OHSS, pelvic pain.
Drug Interactions
Enhanced follicular response w/ clomiphene citrate.
ATC Classification
G03GA02 - human menopausal gonadotrophin ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
75 IU: D; 600 IU/1,200 IU: S
Presentation/Packing
Form
Menopur inj 1,200 IU
Packing/Price
(+ 1 mL pre-filled syringe solvent) 1 mL x 1's
Form
Menopur inj 600 IU
Packing/Price
(+ 1 mL pre-filled syringe solvent) 1 mL x 1's
Form
Menopur inj 75 IU
Packing/Price
(+ solvent) 1 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in